NCT03419559View on ClinicalTrials.gov

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2024

Conditions
Non Small Cell Lung Cancer
Interventions
BIOLOGICAL

LN-145

adoptive cell therapy (ACT) with autologous TIL therapy

DRUG

Durvalumab

PD-L1 antagonist monoclonal antibody

Trial Locations (8)

15232

UPMC Cancer Center, Pittsburgh

37232

Vanderbilt University, Nashville

40202

University of Louisville James Graham Brown Cancer Center, Louisville

48201

Karmanos Cancer Institute, Detroit

90095

University of California, Los Angeles, Santa Monica Hematology/Oncology, Los Angeles

92093

University of California San Diego, Moores Cancer Center, La Jolla

07960

Morristown Medical Center Atlantic Hematology Oncology, Morristown

98195-0001

University of Washington Medical Center, Seattle

Sponsors
All Listed Sponsors
lead

Iovance Biotherapeutics, Inc.

INDUSTRY